Clinical Trial: NCT03414684
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-09-09 |
Study Overview
Brief Summary
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.
The interventions involved in this study are:
- Carboplatin
- Nivolumab
Official Title
A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Carboplatin
- Drug: Nivolumab
Other Study ID Numbers
- 17-512
- CA209-9JX
Start Date (Actual)
2018-01-30
Primary Completion Date (Actual)
2021-09-28
Study Completion Date (Actual)
2026-08-05
Enrollment (Actual)
78
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-09-09 |
Study Overview
Brief Summary
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.
The interventions involved in this study are:
- Carboplatin
- Nivolumab
Official Title
A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Carboplatin
- Drug: Nivolumab
Other Study ID Numbers
- 17-512
- CA209-9JX
Start Date (Actual)
2018-01-30
Primary Completion Date (Actual)
2021-09-28
Study Completion Date (Actual)
2026-08-05
Enrollment (Actual)
78
Study Type
Interventional
Phase
Phase 2